TXG

10x Genomics is a high-quality life-sciences tools franchise in the middle of a genuine financial inflection. FY2025 net loss narrowed to -$43.5M from -$183M (+76% YoY), operating loss shrank to -$61M, and operating cash flow swung to +$136M from a near-zero base (+1,942% YoY) against only $5.9M of capex — so the business now self-funds. The balance sheet is a fortress: $474M cash, $796M equity, zero long-term debt, current ratio ~4.5x and liabilities/equity of just 0.31x. Gross margin of 69.1% confirms the consumables razor-and-blade model still has real pricing power, and the installed base is compounding (cumulative instruments 7,039→8,046; Chromium consumable reactions 310,900→378,300, Xenium 10,800→14,500), which is the leading indicator of durable recurring revenue.

The problem is the top line. Revenue grew just 5.2% to $643M, and the longer arc is a stall, not a ramp: $619M (2023) → $611M (2024) → $643M (2025). The MD&A and Risk Factors pin the cause squarely on the demand environment — explicit dependence on academic/government research funding and R&D spend by institutions, plus China and Asia-Pacific exposure to tariffs, export restrictions and 'Chinese regulations.' Heavy reliance on the single Chromium franchise and on managing product transitions that can cannibalize existing sales adds fragility. The company is still net-unprofitable (ROE -5.5%), carries a -$1.51B accumulated deficit, and a multi-class share structure leaves outside holders with limited control.